Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance
Related Posts
Goldstein B, Uloko M, Okamuro K, Moore M, Peters BR, Blumenthal J, Marinkovic M, Anger J. Sexual health outcomes following gender affirming metoidioplasty: a systematic[...]
Kasperkiewicz M, Ludwig RJ, Curman P. Bidirectional risk between autoimmune blistering diseases and posttraumatic stress disorder. J Eur Acad Dermatol Venereol. 2025 Oct 17. doi:[...]
Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, Ryg U, Schulz-Jaavall M, Weidhaas JB, Santoso M, Parmisano S, Calais J, Reiter[...]